Physician profile
Imad Bitar
NPI 1821267998
$18,380.05
in general payments reported to CMS, 2019-2025
28 companies · $3,377 in 2025
The $3,377 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,237 · 2020: $1,761 · 2021: $2,935 · 2022: $2,653 · 2023: $3,200 · 2024: $3,216 · 2025: $3,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,793.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,498.55 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $2,721.09 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,466.85 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,311.46 | 2019-2025 | |
| Janssen Biotech, INC. | $1,189.32 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Glaxosmithkline, LLC. | $1,073.49 | 2019-2025 | Benlysta |
| Pfizer INC. | $980.58 | 2019-2025 | |
| Genentech USA, INC. | $750.58 | 2019-2025 | Actemra, Gazyva |
| Astrazeneca Pharmaceuticals Lp | $691.74 | 2022-2025 | Saphnelo, Evusheld |
| E.R. Squibb & Sons, L.L.C. | $630.38 | 2019-2025 | Orencia |
| Radius Health, INC. | $595.57 | 2019-2025 | |
| Horizon Therapeutics Plc | $583.10 | 2020-2023 | Krystexxa |
| Octapharma USA, INC. | $482.13 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Genzyme Corporation | $416.78 | 2020-2025 | |
| Aurinia Pharma U.S., INC. | $363.88 | 2022-2025 | Lupkynis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.41 | 2021-2025 | Ofev, Cyltezo |
| Lilly USA, LLC | $331.03 | 2020-2024 | Taltz |
| Fresenius Kabi USA, LLC | $305.16 | 2023-2025 | Idacio |
| Sobi, INC | $168.08 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $128.36 | 2019-2023 | Euflexxa |
| Ani Pharmaceuticals, INC. | $103.39 | 2024-2025 | Purified Cortrophin Gel |
| Pacira Therapeutics, INC. | $57.04 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $42.46 | 2019 | |
| Mallinckrodt Hospital Products INC. | $31.22 | 2021-2025 | Acthar |
| Kiniksa Pharmaceuticals International, Plc | $27.57 | 2024 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $27.41 | 2025 | Strensiq |
| Depuy Synthes Sales INC. | $23.17 | 2019 | |
| Sandoz INC. | $16.25 | 2025 | Jubbonti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imad Bitar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.